ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.
Abstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults.Journal of neuro-oncology · 2022Pooled it
- N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.Neuro-oncology · 2019Trial
- A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.Neuro-oncology · 2025Review
- The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines.Current oncology reports · 2025Article
- Perspectives on cancer therapy-synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges.Cell death discovery · 2025Review
- Current status of precision oncology in adult glioblastoma.Molecular oncology · 2024Review
- A longer time to relapse is associated with a larger increase in differences between paired primary and recurrent IDH wild-type glioblastomas at both the transcriptomic and genomic levels.Acta neuropathologica communications · 2024Article
- Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma.Journal of cancer research and clinical oncology · 2023Article
- Article
- Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer.Science translational medicine · 2023Article
- The dark side of mRNA translation and the translation machinery in glioblastoma.Frontiers in cell and developmental biology · 2023Review
- A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.Cancer reports (Hoboken, N.J.) · 2022Article
- Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.Neuro-oncology · 2022Article
- Simple approach for the histomolecular diagnosis of central nervous system gliomas based on 2021 World Health Organization Classification.World journal of clinical oncology · 2022Review
- Antitumor activity of irinotecan with ellagic acid in C6 glioma cells.Revista da Associacao Medica Brasileira (1992) · 2022Article
- The landscape of receptor-mediated precision cancer combination therapy via a single-cell perspective.Nature communications · 2022Article
- Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma.International journal of molecular sciences · 2022Review
- Identification of key genes involved in the recurrence of glioblastoma multiforme using weighted gene co-expression network analysis and differential expression analysis.Bioengineered · 2021Article
Corrections and comments
- Commented on by
Authors and funding
26 authors.
Sara A ByronIntegrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, Arizona.
Nhan L TranDepartments of Cancer Biology and Neurosurgery, Mayo Clinic Arizona, Scottsdale, Arizona.
Rebecca F HalperinQuantitative Medicine & Systems Biology Division, Translational Genomics Research Institute, Phoenix, Arizona.
Joanna J PhillipsDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
John G KuhnCollege of Pharmacy, University of Texas Health Science Center, San Antonio, Texas.
John F de GrootDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Howard ColmanDepartment of Neurosurgery, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah.
Keith L LigonCenter for Neuro-Oncology, Dana-Farber Cancer Center, Boston, Massachusetts.
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
Timothy F CloughesyDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Ingo K MellinghoffDepartment of Neurology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Nicholas A ButowskiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Jennie W TaylorDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Jennifer L ClarkeDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Susan M ChangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Mitchel S BergerDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Annette M MolinaroDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Gerald M MaggioraCancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona.
Sen PengCancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona.
Sara NasserNeurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona.
Winnie S LiangIntegrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, Arizona.
Jeffrey M TrentGenetic Basis of Human Disease Division, Translational Genomics Research Institute, Phoenix, Arizona.
Michael E BerensCancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona.
John D CarptenDepartment of Translational Genomics, University of Southern California, Los Angeles, California.
David W CraigDepartment of Translational Genomics, University of Southern California, Los Angeles, California.
Michael D PradosDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California. Michael.Prados@ucsf.edu.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MUSC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4MTargeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Benjamin Harris Kann · 2013 to 2026
$33.5MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2MGenetic evolution of glioblastomas during radiation and temozolomide therapyR01CA188228 · NCI · DANA-FARBER CANCER INST · PI BEROUKHIM, RAMEEN, CHAKRAVARTI, ARNAB · 2015 to 2025
$6.9MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P50 CA165962NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA188228Wellcome Trust
Abstract
PubMed holds no abstract for this paper.
Indexed as
Genetic VariationGenomicsAdultAgedBiomarkers, TumorClinical Decision-MakingCombined Modality TherapyDisease ManagementDisease ProgressionExome SequencingFemaleGenome-Wide Association StudyGlioblastomaHumansImmunohistochemistryMaleBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.